Research Abstracts


Deadline to submit a Research Abstract: Tuesday, 19 October, 2021 at 11:59 p.m. EDT
Submitted abstracts can be edited until the deadline.


A research abstract must include the following information (limited to 2,140 characters, not including spaces):
  • Title
  • Brief statement of Purpose of the study (goal or hypothesis being tested)
  • Statement of Methods and procedures used
  • Summary of Results, presented in sufficient detail to support the conclusion
  • Study Conclusion
Note: abstracts undergo a blind review process; therefore, abstain from using institution names within the abstract. If accepted, you may update your presentation accordingly.


The Full Name, Affiliation, Email Address, and Disclosure Statement for the Presenting Author and each co-author must be included. There is no limit to the number of authors, and author information is not counted towards the character limit.

The Submitting Author is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission.

Submission Categories

Your abstract may be submitted into only one category. Submission of the same abstract into multiple categories is not permitted. Submission of one study as several different abstracts is also not permitted. If the abstracts in question are not different enough to be considered separate studies, or if the same abstract is submitted into multiple categories, all versions may be rejected.

Abstract Submission Categories are separated into four Core Therapies:
  • Advanced Heart Failure and Transplantation (HEART)
  • Advanced Lung Failure and Transplantation (LUNG)
  • Mechanical Circulatory Support (MCS)
  • Pulmonary Vascular Disease (PAH and CTEPH) (PVD)
PRIMARY CORE THERAPY: Advanced Heart Failure and Transplantation (HEART)
  • HEART–Access to Care/Caregiver
  • HEART–Basic Science-Immunology, Inflammation
  • HEART–Basic Science-Models of Organ Preservation, Perfusion and Graft Injury
  • HEART–Basic Science-Translational Research/Other
  • HEART–Basic Science-Xenotransplantation/Regenerative Medicine/Artificial Organs
  • HEART–Cardiac Allograft Vasculopathy
  • HEART–Cardiogenic Shock
  • HEART–Clinical Ex-Vivo Perfusion and Preservation
  • HEART–Compliance/Adherence/Psychosocial Aspects
  • HEART–Complications Other
  • HEART–Congenital Heart Disease Management
  • HEART–COVID 19 Vaccine Pre- and Post-Transplant
  • HEART–COVID-19 Non-Vaccine related
  • HEART–Critical Care Medicine/Peri-operative/Intra-operative Management
  • HEART–Diagnostics/Patient Management/Patient Care Pathways
  • HEART–Donor Management
  • HEART–Economics, Ethics, Public Policy/Health Equity
  • HEART–Immunology, Inflammation (Clinical)
  • HEART–Infectious Diseases - Diagnostics and Complications
  • HEART–Infectious Diseases - Management and Therapeutics
  • HEART–Organ Allocation
  • HEART–Other (Clinical)
  • HEART–Outcomes (Effectiveness)
  • HEART–Outcomes (Other)
  • HEART–Outcomes (Risk Prediction/Modelling)
  • HEART–Outcomes (Safety)
  • HEART–Palliative Care/Self Care/Symptom Management
  • HEART–Pathology
  • HEART–Patient Selection for Advanced Therapies/Rehabilitation
  • HEART–Pediatrics-Basic and Translational Research
  • HEART–Pediatrics-Complications
  • HEART–Pediatrics-Heart Failure
  • HEART–Pediatrics-Other
  • HEART–Pediatrics-Outcomes
  • HEART–Pediatrics-Patient Selection, Organ Allocation, Donor Management
  • HEART–Pharmacology, Therapeutics, Immunosuppression
  • HEART–Primary Graft Dysfunction
  • HEART–Quality of Life/Quality Improvement
  • HEART–Rejection-Antibody Mediated (AMR)
  • HEART–Rejection-Cellular
  • HEART–Telehealth/Remote Monitoring and Interventions
PRIMARY CORE THERAPY: Advanced Lung Failure and Transplantation (LUNG)
  • LUNG–Basic Science-Immunology, Inflammation
  • LUNG–Basic Science-Organ Preservation, Perfusion and Graft Injury
  • LUNG–Basic Science-Translational Research/Other
  • LUNG–Basic Science-Xenotransplantation/Regenerative Medicine/Artificial Organs
  • LUNG–Caregiver and Psychosocial Aspects/Adherence to Care
  • LUNG–Chronic Lung Allograft Dysfunction (CLAD)
  • LUNG–Clinical Ex-Vivo Perfusion and Preservation
  • LUNG–Critical Care Medicine/Peri-operative Care
  • LUNG–Diagnostics and Pathology
  • LUNG–Donor Management and Organ Allocation
  • LUNG–ECLS/Short-Term Support
  • LUNG–Economics, Ethics, Public Policy
  • LUNG–Immunology, Inflammation (Clinical)
  • LUNG–Infectious Diseases
  • LUNG–Other/Complications (Clinical)
  • LUNG–Palliative Care/Symptom Management
  • LUNG–Pediatrics
  • LUNG–Pharmacology, Therapeutics, Immunosuppression
  • LUNG–Primary Graft Dysfunction
  • LUNG–Quality Improvement/Service Development/Access to Care
  • LUNG–Quality of Life/Frailty/Patient Reported Outcomes
  • LUNG–Recipient Selection for Transplant and/or Advanced Therapies
  • LUNG–Rejection (Acute)
  • LUNG–Surgical Aspects of Lung Transplantation
  • LUNG–Survival/Prognostication
PRIMARY CORE THERAPY: Mechanical Circulatory Support (MCS)
  • MCS–Basic Science/Translational Research
  • MCS–Bleeding/Thrombosis/Anticoagulation
  • MCS–Cardiac Complications/Right Heart Failure
  • MCS–COVID-19
  • MCS–Critical Care Medicine/Physiology
  • MCS–Devices and Engineering
  • MCS–Diagnostics/Imaging
  • MCS–Digital Healthcare/Remote Monitoring
  • MCS–ECMO/Short-Term Support
  • MCS–Infectious Diseases
  • MCS–Myocardial Recovery
  • MCS–Neurological Dysfunction
  • MCS–Other
  • MCS–Outcomes Research
  • MCS–Palliative Care/Symptom Management/Self Care
  • MCS–Patient Management
  • MCS–Patient Selection for Transplant and/or Advanced Therapies
  • MCS–Pediatrics/Congenital Heart Disease
  • MCS–Peri-operative/Intra-operative Management
  • MCS–Pharmacology and Therapeutics
  • MCS–Quality of Life/Psychosocial Aspects
  • MCS–Surgical Techniques  
PRIMARY CORE THERAPY: Pulmonary Vascular Disease (PVD)
  • PVD–Basic Science/Translational Research
  • PVD–Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • PVD–COVID-19
  • PVD–Imaging, Physiology, Treatment for the Right Ventricle
  • PVD–Nursing and Psychosocial Aspects
  • PVD–Other (Clinical)
  • PVD–Pediatric Pulmonary Hypertension
  • PVD–Pulmonary Arterial Hypertension (PAH)
  • PVD–Pulmonary Hypertension Secondary to Left Heart Disease
  • PVD–Pulmonary Hypertension Secondary to Lung Disease

Practice Areas

You will be asked to select the Primary Practice Area most relevant to your research abstract, as well as any additional practice areas applicable.
  • Anesthesiology & Critical Care
  • Cardiology
  • Cardiothoracic Surgery
  • Infectious Diseases
  • Nursing and Allied Health
  • Pathology
  • Pediatrics
  • Pharmacy and Pharmacology
  • Pulmonology
  • Research & Immunology


All accepted Research Abstracts will be published exactly as submitted in the April 2022 Supplement of the Journal of Heart and Lung Transplantation.

Visit our FAQ Page for answers to common submission questions.